Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$65.20
+1.2%		$63.53
$49.26
▼
$70.98
$12.62B0.242.05 million shs459,359 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$528.05
+0.9%		$530.76
$393.61
▼
$615.00
$12.20B-0.98336,699 shs75,493 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$144.25
+4.5%		$115.15
$23.30
▼
$155.44
$9.06B2.221.52 million shs848,691 shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$40.14
+0.0%		$48.36
$29.45
▼
$60.91
$3.21B1.931.09 million shs252,259 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-2.95%-0.28%-4.32%+17.14%+21.28%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-3.11%-2.04%+3.09%+4.68%+22.95%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.49%+7.84%+16.47%+66.65%+436.94%
Veracyte, Inc. stock logo
VCYT
Veracyte
-2.60%-5.44%-2.69%-21.74%+25.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$65.20
+1.2%		$63.53
$49.26
▼
$70.98
$12.62B0.242.05 million shs459,359 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$528.05
+0.9%		$530.76
$393.61
▼
$615.00
$12.20B-0.98336,699 shs75,493 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$144.25
+4.5%		$115.15
$23.30
▼
$155.44
$9.06B2.221.52 million shs848,691 shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$40.14
+0.0%		$48.36
$29.45
▼
$60.91
$3.21B1.931.09 million shs252,259 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-2.95%-0.28%-4.32%+17.14%+21.28%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-3.11%-2.04%+3.09%+4.68%+22.95%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.49%+7.84%+16.47%+66.65%+436.94%
Veracyte, Inc. stock logo
VCYT
Veracyte
-2.60%-5.44%-2.69%-21.74%+25.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.70
Moderate Buy$89.1736.78% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6432.50% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.50
Moderate Buy$98.45-31.75% Downside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.82
Moderate Buy$55.7838.95% Upside

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/15/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$60.00
9/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$52.00 ➝ $65.00
9/9/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
BWS Financial logo
BWS Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$45.00
9/9/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$144.00
9/9/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$52.00 ➝ $65.00
9/3/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/1/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$88.00 ➝ $90.00
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $105.00
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.92$2.80 per share23.27$31.68 per share2.06
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.73N/AN/A$26.54 per share19.90
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M24.02N/AN/A$7.84 per share18.40
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M6.24$1.45 per share27.67$16.57 per share2.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37176.2611.960.482.14%5.32%3.69%10/26/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A95.14N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$2.22N/AN/AN/A-31.66%-28.64%-19.94%11/13/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.4128.3626.07N/A20.37%9.26%8.61%11/3/2026 (Estimated)

Latest VCYT, TWST, BMRN, and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.5063-$0.56-$0.0538-$0.56$114.55 million$118.38 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/30/2026Q2 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.4103$0.54+$0.1297$0.31$144.59 million$150.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.67
2.38
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.16
8.80

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
97962.71 million60.78 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
75580.39 million79.11 millionOptionable

Recent News About These Companies

Shattuck Labs (NASDAQ:STTK) & Veracyte (NASDAQ:VCYT) Financial Comparison
September 16 at 4:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027064
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts
September 16 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025833
Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 16 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-veracyte-inc-nasdaq-vcyt-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-09-16/
Veracyte Adds Another Stream to Bladder Franchise, UBS Says
September 15 at 12:49 PM  |  marketscreener.comM
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15 at 10:31 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4946434-veracyte-inc-vcyt-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Veracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 15 at 7:48 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69580720-veracyte-inc-veracyte-acquires-convergent-genomics-expanding-its-urology-diagnostics-portfolio-with-a-urinary-tumor-dna-testing-platform-399.htm
Veracyte Buys Convergent Genomics
September 14 at 9:47 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/veracyte-buys-convergent-genomics-202232974.html
Veracyte Acquires Convergent Genomics For $150 Mln In Cash
September 14 at 9:47 PM  |  rttnews.comhttps://www.rttnews.com/3690830/veracyte-acquires-convergent-genomics-for-150-mln-in-cash.aspx
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 14 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361535/0/en/veracyte-acquires-convergent-genomics-expanding-its-urology-diagnostics-portfolio-with-a-urinary-tumor-dna-testing-platform.html
Why (VCYT) Price Action Is Critical for Tactical Trading
September 13 at 10:40 PM  |  news.stocktradersdaily.comN
Veracyte (NASDAQ:VCYT) Upgraded at UBS Group
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-veracyte-nasdaq-vcyt-upgraded-at-ubs-group-2026-09-12/
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
September 9, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9073988/veracyte-inc-vcyt-shares-surge-33-what-gf-score-of-81-tells-investors
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes
September 9, 2026  |  zacks.comhttps://www.zacks.com/commentary/2986737/3-medical-instruments-stocks-banking-on-genai-to-tackle-industry-woes?cid=cs-stocknewsapi-ft-industry_outlook-2986737
Insider Selling: Veracyte (NASDAQ:VCYT) Insider Sells $564,385.50 in Stock
September 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31009040
Veracyte (NASDAQ:VCYT) Stock Price Down 4.5% After Insider Selling
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005783
Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares
September 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-vcyt-insider-buying-and-selling-2026-09-05/
Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares of Stock
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-veracyte-nasdaq-vcyt-evp-sells-3254-shares-of-stock-2026-09-04/
Veracyte (NASDAQ:VCYT) CFO Sells 3,652 Shares
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-veracyte-nasdaq-vcyt-cfo-sells-3652-shares-2026-09-04/
Phillip Febbo Sells 13,110 Shares of Veracyte (NASDAQ:VCYT) Stock
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-phillip-febbo-sells-13110-shares-of-veracyte-nasdaq-vcyt-stock-2026-09-04/
Veracyte (NASDAQ:VCYT) Shares Down 4.5% After Insider Selling
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-veracyte-nasdaq-vcyt-shares-down-45-after-insider-selling-2026-09-04/
Muna Bhanji Sells 1,864 Shares of Veracyte (NASDAQ:VCYT) Stock
September 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-vcyt-insider-buying-and-selling-2026-09-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$65.19 +0.75 (+1.16%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$528.05 +4.79 (+0.92%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$144.25 +6.15 (+4.45%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$40.14 +0.00 (+0.00%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas